United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $576.93, for a total value of $5,769,300.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,890,130.68. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total value of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total value of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total value of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total value of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.

United Therapeutics Stock Down 1.6%

NASDAQ:UTHR opened at $572.20 on Wednesday. The firm has a market capitalization of $24.18 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 1.65 and a beta of 0.60. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The stock’s 50 day moving average price is $545.81 and its two-hundred day moving average price is $499.25.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $6.19 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the company. Clearstead Advisors LLC boosted its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares during the period. Sage Rhino Capital LLC boosted its holdings in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 24 shares during the period. Independent Advisor Alliance boosted its holdings in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares during the period. Finally, Bessemer Group Inc. boosted its holdings in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on UTHR. TD Cowen boosted their price target on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Royal Bank Of Canada upped their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Finally, Wells Fargo & Company boosted their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $601.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.